Clinical stage biotechnology company Anavex Life Sciences has partnered with Amarantus Bioscience Holdings to provide biomarker services for Anavex’s Alzheimer’s disease (AD) drugs. Anavex’s sigma-1 receptor agonist, Anavex 2-73, is in Phase II trials for Alzheimer’s disease and is in preclinical development for ALS (see March 2014 news story). The company will use Amarantus’ LymPro Test to examine the effect of Anavex 2-73 and Anavex Plus on CD69 biomarker expression in peripheral blood lymphocytes of AD patients. The companies have also agreed to work together on blood-based biomarkers for a potential Phase III clinical trial of these drug candidates. This partnership could help lay the ground for biomarker studies in a future ALS clinical trial.
Click here to read more.